TGFB1 and breast cancer: In conclusion, using nuclear pSMAD2 as a marker for active TGF-β signaling in a large cohort of early-stage breast cancer patients, our findings suggest that TGF-β signaling may play an anti-tumoral role by reducing recurrence risk, challenging its therapeutic targeting in this patient group.